期刊
JOURNAL OF THORACIC DISEASE
卷 5, 期 -, 页码 S579-S592出版社
AME PUBL CO
DOI: 10.3978/j.issn.2072-1439.2013.08.52
关键词
Non-small-cell lung carcinoma (NSCLC); molecular targeted therapy; immunotherapy; epidermal growth factor receptor (EGFR); anaplastic lymphoma kinase (ALK)
Advances in the treatment of non-small cell lung cancer (NSCLC) over the last decade have predominantly involved the development of therapies directed at molecular targets such as mutations in the epidermal growth factor receptor (EGFR) or rearrangements in the anaplastic lymphoma kinase (ALK) gene. Other targets have been discovered at low frequency, with multiple agents approved or in development for treatment of these rare molecular subtypes. The tumour microenvironment has also provided opportunities for therapies targeting angiogenesis and the host immune response. This review will provide an overview of current targeted therapies in NSCLC and promising treatment approaches on the horizon.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据